Stock 300702 ZHEJIANG TIANYU PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Zhejiang Tianyu Pharmaceutical Co., Ltd.

Equities

300702

CNE1000034X1

End-of-day quote Shenzhen S.E.
Other stock markets
 23:00:00 30/05/2024 BST 		5-day change 1st Jan Change
19.35 CNY -0.62% Intraday chart for Zhejiang Tianyu Pharmaceutical Co., Ltd. -4.02% -10.87%
05-31 Zhejiang Tianyu Pharmaceutical Co., Ltd. Announces Dividend Implementation for 2023, Payable on 06 June 2024 CI
05-06 China Approves Tianyu Pharma's Heart Medication MT

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Zhejiang Tianyu Pharmaceutical Co., Ltd. Announces Dividend Implementation for 2023, Payable on 06 June 2024
CI
China Approves Tianyu Pharma's Heart Medication
MT
Tranche Update on Zhejiang Tianyu Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on January 24, 2024.
CI
Zhejiang Tianyu Pharmaceutical Co., Ltd.'s Equity Buyback announced on January 24, 2024, has closed with 1,646,420 shares, representing 0.48% for CNY 27.79 million.
CI
Zhejiang Tianyu Pharmaceutical Co., Ltd. Announces Profit Distribution Proposal for 2023
CI
Tranche Update on Zhejiang Tianyu Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on January 24, 2024.
CI
Zhaoxin Liaowang No. 1 Private Securities Investment Fund managed by Jiangsu Zhaoxin Private Fund Management Co., Ltd. entered into a share transfer agreement to acquire 6.19% stake in Zhejiang Tianyu Pharmaceutical Co., Ltd. from Ganzhou Zhenhan Venture Capital Co., Ltd. for CNY 310 million.
CI
Zhejiang Tianyu Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 50 million worth of its shares.
CI
Zhejiang Tianyu Pharmaceutical Co., Ltd. authorizes a Buyback Plan.
CI
Tianyu Pharmaceutical Unit Passes US FDA's On-Site Inspection
MT
Zhejiang Tianyu Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Zhejiang Tianyu Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Zhuhai Rundu Pharma Gets Supplementary Application Approval For Hypertension Drug
MT
Raw Drug Material of Tianyu Pharma's Unit Passes Regulatory Evaluation
MT
Tianyu Pharmaceutical Unit Gets Approval to Market Hypertension Drug in China
MT
Zhejiang Tianyu Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Zhejiang Tianyu Pharma Unit Gets Marketing Approval For Losartan Potassium Tablets
MT
Tranche Update on Zhejiang Tianyu Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on June 30, 2022.
CI
Zhejiang Tianyu Pharmaceutical Co., Ltd.'s Equity Buyback announced on June 30, 2022, has expired with 2,403,643 shares, representing 0.69% for CNY 58 million.
CI
Zhejiang Tianyu Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 300702 Stock
  4. News Zhejiang Tianyu Pharmaceutical Co., Ltd.
  5. Highlights